BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 29291023)

  • 1. Combined venetoclax and alvocidib in acute myeloid leukemia.
    Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
    Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
    Lee DJ; Zeidner JF
    Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
    [No Abstract]   [Full Text] [Related]  

  • 4. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
    Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
    BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
    Jonas BA; Hou JZ; Roboz GJ; Alvares CL; Jeyakumar D; Edwards JR; Erba HP; Kelly RJ; Röllig C; Fiedler W; Brackman D; Siddani SR; Chyla B; Hilger-Rolfe J; Watts JM
    Hematol Oncol; 2023 Oct; 41(4):743-752. PubMed ID: 37086447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
    Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
    Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.
    Sim KM; Kim SY; Hwang S; Park S; Lee BR; Nam K; Oh S; Kim I
    Chem Biol Interact; 2023 Sep; 382():110554. PubMed ID: 37271215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.
    Zhou L; Zhang Y; Sampath D; Leverson J; Dai Y; Kmieciak M; Nguyen M; Orlowski RZ; Grant S
    Br J Cancer; 2018 Feb; 118(3):388-397. PubMed ID: 29241222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
    Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia
    Schwartz J; Niu X; Walton E; Hurley L; Lin H; Edwards H; Taub JW; Wang Z; Ge Y
    Am J Transl Res; 2016; 8(9):3893-3902. PubMed ID: 27725868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
    Zeidner JF; Karp JE
    Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
    Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
    Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
    Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
    Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia.
    Zhou FJ; Zeng CX; Kuang W; Cheng C; Liu HC; Yan XY; Chen XP; Zhou G; Cao S
    J Cancer; 2021; 12(22):6727-6739. PubMed ID: 34659562
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
    Malarikova D; Jorda R; Kupcova K; Senavova J; Dolnikova A; Pokorna E; Kazantsev D; Nozickova K; Sovilj D; Bellanger C; Chiron D; Andera L; Krystof V; Strnad M; Helman K; Klanova M; Trneny M; Havranek O; Klener P
    Exp Hematol Oncol; 2024 Mar; 13(1):34. PubMed ID: 38528594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.